EDAP TMS SA annual report, Q4 FY2019

EDAP TMS S.A. — 2019 Annual Report Summary

Reporting period: Fiscal year ended December 31, 2019; Form 20-F filed April 16, 2020. This is an annual report, not a standalone 2019 fourth-quarter filing. Financial statements are prepared under U.S. GAAP and reported in euros.

Business context

EDAP develops, manufactures, markets and services minimally invasive medical devices, principally robotic high-intensity focused ultrasound (HIFU) systems for prostate treatment and extracorporeal shockwave lithotripsy (ESWL) equipment for urinary stones. Its two divisions are HIFU and Urology Devices and Services (UDS); UDS also distributes other urology products. The company reported 216 employees and operations across Europe, the Americas and Asia.

Financial performance and liquidity

Metric (€ millions unless stated)20192018
Total revenue44.939.2
Gross profit / gross margin21.0 / 46.8%16.9 / 43.2%
Operating expenses18.818.2
Operating income (loss)2.2(1.3)
Net income (loss)1.5(0.3)
Basic and diluted EPS€0.05(€0.01)
Net cash from operating activities3.80.2
Cash and cash equivalents at year-end20.919.5
Total current assets / current liabilities42.1 / 17.540.4 / 16.8
Long-term debt at year-end1.41.8

Short-term borrowings were €3.5 million, mainly receivables factored with EDAP retaining collection risk. Finance-lease obligations were €1.0 million and operating-lease obligations €2.7 million at year-end. Total shareholders’ equity was €27.4 million. Operating cash flow improved substantially year over year; investing activities used €1.5 million and financing activities used €0.7 million in 2019. Cash increased by €1.4 million to €20.9 million.

Net sales rose 14.6%. HIFU revenue increased 28.1% to €14.1 million, including 13 HIFU device sales (11 Focal One and two Ablatherm); U.S. HIFU device sales increased to nine from two. UDS revenue rose 9.3% to €30.8 million, primarily from distribution products and recurring consumables, parts and services. Operating profitability improved in both divisions: HIFU reported €0.5 million operating profit versus a €2.3 million loss; UDS reported €3.0 million versus €2.3 million profit. Approximately 40% of consolidated net sales came from Asia, and 75% of sales were exports outside mainland France.

Material changes versus 2018

  • Revenue growth, improved gross margin and lower research and development expense contributed to a return to operating and net profitability. Gross margin benefited from a higher HIFU sales mix and increased sales spread over fixed costs.
  • Operating expenses increased 3.1%: selling and marketing rose to €10.9 million and general and administrative expense to €4.2 million; R&D expense declined to €3.7 million, net of grants and tax credits.
  • Net financial expense was €0.1 million, compared with €0.8 million financial income in 2018, which included a €0.9 million warrant fair-value gain. No warrants remained outstanding at year-end 2018 or 2019.
  • Adoption of ASC 842 lease accounting in 2019 added operating lease right-of-use assets and liabilities; the company recorded approximately €3.5 million at adoption. The filing says this materially affected the balance sheet but not the income statement.

Outlook, risks and unusual items

  • COVID-19: As of the filing date, management expected treatment cancellations and delays to device sales as hospitals deferred purchases. Most employees were working remotely, supply-chain activity was minimized, and the Lyon facility was closed from April 1, 2020, with minimal staff for scheduled shipments. Management cited cash reserves and inventory as buffers but could not estimate the duration or full impact of disruption.
  • Investment plans: Management expected R&D spending in Europe to rise to approximately 10.6% of revenue from 2020, with continued clinical studies, regulatory work (particularly Japan), reimbursement efforts and development of HIFU applications beyond prostate cancer. Sales and marketing expense was also expected to increase.
  • Products and regulation: Endo-UP was expected to become commercially available in Europe in 2020, subject to CE marking; EDAP planned to stop manufacturing the Sonolith i-sys in 2020. The EU Medical Device Regulation was due to apply from May 26, 2020, and compliance remained an execution risk. HIFU reimbursement and market adoption remained uncertain; the new U.S. Category 1 CPT code was expected to take effect in 2021, subject to the process described in the filing.
  • Key business risks: Continued profitability depends partly on HIFU commercialization, clinical evidence, regulatory approvals and reimbursement. Other risks include mature and price-competitive ESWL markets, reliance on distributors and certain single-source suppliers, a single principal manufacturing site, foreign-exchange exposure, and lengthy hospital purchasing cycles.
  • Financial reporting controls: Management and KPMG reported a material weakness in general IT controls, particularly program-change logging, validation and acceptance-testing documentation, and segregation of duties. Management said the weakness was not fully remediated; disclosure controls and internal control over financial reporting were deemed ineffective, and KPMG issued an adverse opinion on ICFR. KPMG separately issued an unqualified opinion on the consolidated financial statements; additional procedures found no material misstatement or need for restatement.
  • Other items: EDAP decided in February 2020 to liquidate its loss-making Italian subsidiary and continue activities through a distributor. In March 2020, CEO Marc Oczachowski also became board chairman. Shareholders authorized potential share issuances and options in 2019, but the filing reported none allocated under those authorizations by April 16, 2020. No dividends were paid for 2015–2018, and none were anticipated for 2019 or the foreseeable future.

Most important facts for investors to verify

  • Whether revenue growth and the return to profitability persist, especially HIFU device sales and the U.S. contribution.
  • Actual COVID-19 effects on treatment volumes, device orders, manufacturing, cash flow and working capital after the filing date.
  • Progress in remediating the IT-controls material weakness and whether subsequent reporting confirms effective controls.
  • HIFU reimbursement, clinical-study outcomes and regulatory progress, including Japan and the EU MDR transition; and CE clearance and launch timing for Endo-UP.
  • Liquidity and debt details, including recourse factoring, lease obligations and the ability to meet contractual payments if operating cash flow weakens.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.